Affimed N.V. (AFMD)’s Financial Results Comparing With Translate Bio Inc. (NASDAQ:TBIO)

Affimed N.V. (NASDAQ:AFMD) and Translate Bio Inc. (NASDAQ:TBIO) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. N/A 0.00 N/A -0.37 0.00
Translate Bio Inc. 2.89M 220.92 109.84M -2.17 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Affimed N.V. and Translate Bio Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Affimed N.V. and Translate Bio Inc.

Net Margins Return on Equity Return on Assets
Affimed N.V. 0.00% -43.9% -26.7%
Translate Bio Inc. -3,800.69% 0% -47.9%


The current Quick Ratio of Affimed N.V. is 3 while its Current Ratio is 3. Meanwhile, Translate Bio Inc. has a Current Ratio of 10.5 while its Quick Ratio is 10.5. Translate Bio Inc. is better positioned to pay off its short-term and long-term debts than Affimed N.V.

Analyst Recommendations

Ratings and Recommendations for Affimed N.V. and Translate Bio Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Affimed N.V. 0 0 1 3.00
Translate Bio Inc. 0 0 1 3.00

Affimed N.V.’s consensus price target is $8, while its potential upside is 134.60%. Competitively Translate Bio Inc. has an average price target of $21, with potential upside of 67.20%. Based on the data delivered earlier, Affimed N.V. is looking more favorable than Translate Bio Inc., analysts view.

Insider and Institutional Ownership

The shares of both Affimed N.V. and Translate Bio Inc. are owned by institutional investors at 41.8% and 59.9% respectively. 8.15% are Affimed N.V.’s share owned by insiders. On the other hand, insiders owned about 31.15% of Translate Bio Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. -3.92% -10.68% 0.29% -15.52% 49.13% 10.29%
Translate Bio Inc. 11.68% -8.11% 41.19% 60.31% 0% 38.93%

For the past year Affimed N.V. has weaker performance than Translate Bio Inc.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.